AU2018380155B2 - Compositions for the treatment of breast and prostate cancer - Google Patents

Compositions for the treatment of breast and prostate cancer Download PDF

Info

Publication number
AU2018380155B2
AU2018380155B2 AU2018380155A AU2018380155A AU2018380155B2 AU 2018380155 B2 AU2018380155 B2 AU 2018380155B2 AU 2018380155 A AU2018380155 A AU 2018380155A AU 2018380155 A AU2018380155 A AU 2018380155A AU 2018380155 B2 AU2018380155 B2 AU 2018380155B2
Authority
AU
Australia
Prior art keywords
seviteronel
dexamethasone
amount
dosing regimen
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018380155A
Other languages
English (en)
Other versions
AU2018380155A1 (en
Inventor
Edwina BASKIN-BEY
Joel EISNER
Elizabeth WOODSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kembi Therapeutics Pty Ltd
Original Assignee
Kembi Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kembi Therapeutics Pty Ltd filed Critical Kembi Therapeutics Pty Ltd
Publication of AU2018380155A1 publication Critical patent/AU2018380155A1/en
Assigned to KEMBI THERAPEUTICS PTY LTD reassignment KEMBI THERAPEUTICS PTY LTD Request for Assignment Assignors: INNOCRIN PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2018380155B2 publication Critical patent/AU2018380155B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018380155A 2017-12-07 2018-12-06 Compositions for the treatment of breast and prostate cancer Active AU2018380155B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595918P 2017-12-07 2017-12-07
US62/595,918 2017-12-07
PCT/US2018/064229 WO2019113301A1 (en) 2017-12-07 2018-12-06 Compositions for the treatment of breast and prostate cancer

Publications (2)

Publication Number Publication Date
AU2018380155A1 AU2018380155A1 (en) 2020-07-02
AU2018380155B2 true AU2018380155B2 (en) 2024-07-04

Family

ID=66750338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018380155A Active AU2018380155B2 (en) 2017-12-07 2018-12-06 Compositions for the treatment of breast and prostate cancer

Country Status (8)

Country Link
US (2) US20210292410A1 (https=)
EP (1) EP3720427A4 (https=)
JP (1) JP7437576B2 (https=)
CN (1) CN111698985B (https=)
AU (1) AU2018380155B2 (https=)
CA (1) CA3084997A1 (https=)
TW (1) TWI809015B (https=)
WO (1) WO2019113301A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
US12357615B2 (en) 2018-10-11 2025-07-15 Kembi Therapeutics Pty Ltd Compositions for the treatment of brain tumors
CA3158748A1 (en) * 2019-10-25 2021-04-29 Garvan Institute Of Medical Research Methods of treating cancer using androgen receptor antagonists
US12150776B2 (en) * 2021-04-26 2024-11-26 Wisconsin Alumni Research Foundation & AIQ Solutions, Inc. System and method for monitoring multiple lesions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
KR101848077B1 (ko) * 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EP2751117A4 (en) * 2011-08-30 2015-06-24 Innocrin Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza

Also Published As

Publication number Publication date
JP2021505669A (ja) 2021-02-18
CN111698985B (zh) 2023-10-31
TWI809015B (zh) 2023-07-21
WO2019113301A1 (en) 2019-06-13
US20210154209A1 (en) 2021-05-27
CA3084997A1 (en) 2019-06-13
EP3720427A4 (en) 2021-09-15
JP7437576B2 (ja) 2024-02-26
CN111698985A (zh) 2020-09-22
AU2018380155A1 (en) 2020-07-02
US20210292410A1 (en) 2021-09-23
US11980626B2 (en) 2024-05-14
TW201938157A (zh) 2019-10-01
EP3720427A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
US11980626B2 (en) Compositions for treatment of breast and prostate cancer
AU2023202813B2 (en) Methods of treating prostate cancer
EP3908319B1 (en) Metalloenzyme inhibitor compounds
JP2019533660A (ja) 急性腎障害を処置する方法
AU2020327022B2 (en) Method of treating cancer
US20230039711A1 (en) Ahr inhibitors and uses thereof
US20050070565A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
CN117177745A (zh) 包含特定hdac6抑制剂和至少一种ctla4检查点抑制剂的组合
US12357615B2 (en) Compositions for the treatment of brain tumors
CA3230285A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2024023696A1 (en) Dosing regimen for a nlrp3 inhibitor
JP2025521628A (ja) カルシニューリン阻害剤の間欠的投与のための組成物
JP2005075747A (ja) 痒み抑制剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KEMBI THERAPEUTICS PTY LTD

Free format text: FORMER APPLICANT(S): INNOCRIN PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)